Filtered By:
Drug: Provigil

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 19 results found since Jan 2013.

MIDAS (Modafinil in Debilitating Fatigue After Stroke) Clinical Sciences
Conclusions—Stroke survivors with nonresolving fatigue reported reduced fatigue and improved quality of life after taking 200 mg daily treatment with modafinil.Clinical Trial Registration—URL: https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=368268. Unique identifier: ACTRN12615000350527.
Source: Stroke - April 24, 2017 Category: Neurology Authors: Andrew Bivard, Thomas Lillicrap, Venkatesh Krishnamurthy, Elizabeth Holliday, John Attia, Heather Pagram, Michael Nilsson, Mark Parsons, Christopher R. Levi Tags: Clinical Studies, Ischemic Stroke Original Contributions Source Type: research

Modafinil in Recovery after Stroke (MIRAS): A Retrospective Study
Background and Purpose: Acute rehabilitation is known to enhance stroke recovery. However, poststroke lethargy and fatigue can hinder participation in rehabilitation therapies. We hypothesized that in patients with moderate to severe stroke complicated by poststroke fatigue and lethargy early stimulant therapy with modafinil increases favorable discharge disposition defined as transfer to acute inpatient rehabilitation or home. Methods: We retrospectively reviewed a cohort of patients with acute stroke admitted to the stroke service over a 3-year period.
Source: Journal of Stroke and Cerebrovascular Diseases - March 6, 2020 Category: Neurology Authors: Danielle B. Cross, Jonathan Tiu, Chaitanya Medicherla, Koto Ishida, Aaron Lord, Barry Czeisler, Christopher Wu, Danielle Golub, Amabel Karoub, Christopher Hernandez, Shadi Yaghi, Jose Torres Source Type: research

Exploring the Economic Benefits of Modafinil for Post-Stroke Fatigue in Australia: A Cost-Effectiveness Evaluation
Post-stroke fatigue remains a substantial ‘silent disability’, affecting up to three-quarters of stroke survivors,1,2 and rating among the worst symptoms experienced by nearly half of stroke survivors.3 On the spectrum of stroke complications, fatigue receives considerably less attention than more visible physical disabilities,4 despite fatigue adversely affecting clinical outcomes and quality of life, and being an independent predictor of institutionalisation, dependence in activities of daily living, poorer functional outcomes, and death.
Source: Journal of Stroke and Cerebrovascular Diseases - October 14, 2020 Category: Neurology Authors: Beata Bajorek, Lan Gao, Tom Lillicrap, Andrew Bivard, Carlos Garcia-Esperon, Mark Parsons, Neil Spratt, Elizabeth Holliday, Chris Levi Source Type: research

Modafinil for the Improvement of Patient Outcomes Following Traumatic Brain Injury
Conclusion. Modafinil is a central nervous system stimulant with well-established effectiveness in the treatment of narcolepsy and shift-work sleep disorder. There is conflicting evidence about the benefits of modafinil in the treatment of fatigue and EDS secondary to TBI. One randomized, controlled study states that modafinil does not significantly improve patient wakefulness, while another concludes that modafinil corrects EDS but not fatigue. An observational study provides evidence that modafinil increases alertness in fatigued patients with past medical history of brainstem diencephalic stroke or multiple sclerosis. ...
Source: Innovations in Clinical Neuroscience - April 1, 2018 Category: Neuroscience Authors: ICNS Online Editor Tags: Current Issue Review excessive daytime sleep fatigue head injury modafinil stroke TBI traumatic brain injury Source Type: research

Therapeutic effects of modafinil in ischemic stroke; possible role of NF- κB downregulation.
Conclusion: Our findings demonstrate a promising therapeutic effect of modafinil for animal models of stroke. PMID: 31542978 [PubMed - as supplied by publisher]
Source: Immunopharmacology and Immunotoxicology - September 25, 2019 Category: Allergy & Immunology Tags: Immunopharmacol Immunotoxicol Source Type: research

Amantadine and Modafinil as Neurostimulants During Post-stroke Care: A Systematic Review
AbstractAmantadine and modafinil are neurostimulants that may improve cognitive and functional recovery post-stroke, but the existing study results vary, and no comprehensive review has been published. This systematic review describes amantadine and modafinil administration practices post-stroke, evaluates timing and impact on clinical effectiveness measures, and identifies the incidence of potential adverse drug effects. A librarian-assisted search of the MEDLINE (PubMed) and EMBASE databases identified all English-language publications with “amantadine” or “modafinil” in the title or abstract from inception throu...
Source: Neurocritical Care - May 11, 2020 Category: Neurology Source Type: research

Modafinil for post ‐stroke patients: a systematic review
ConclusionBased on two small randomized controlled trial, which provided very low quality evidence, the effects (benefits and harms) of modafinil for stroke patients are unclear and do not support its routinely use in clinical practice for this clinical situation.This article is protected by copyright. All rights reserved.
Source: International Journal of Clinical Practice - November 16, 2018 Category: Internal Medicine Authors: Rafael Leite Pacheco, Carolina de Oliveira Cruz Latorraca, Luciana Di Giovanni Marques da Silva, Daniel Barbuda Guimaraes de Meneses Ferreira, Cristiano de Abreu Amorim Fernandes, Nicole Dittrich Hosni, Ana Luiza Cabrera Martimbianco, Daniela Viann Tags: Systematic Review Source Type: research

Amantadine and Modafinil as Neurostimulants Following Acute Stroke: A Retrospective Study of Intensive Care Unit Patients
ConclusionsNeurostimulant administration during acute stroke care may improve wakefulness. Future controlled studies with a neurostimulant administration protocol, prospective evaluation, and discretely defined response and safety criteria are needed to confirm these encouraging findings.
Source: Neurocritical Care - May 19, 2020 Category: Neurology Source Type: research

Modafinil May Alleviate Poststroke Fatigue: A Randomized, Placebo-Controlled, Double-Blinded Trial Clinical Sciences
Conclusions— There were no significant differences between the 2 groups with regard to the primary end point. There were secondary significant outcomes that should be explored in future trials. Clinical Trial Registration— URL: http://www.clinicaltrials.gov. Unique identifier: NCT01800097.
Source: Stroke - November 23, 2015 Category: Neurology Authors: Poulsen, M. B., Damgaard, B., Zerahn, B., Overgaard, K., Rasmussen, R. S. Tags: Behavioral/Psychosocial Treatment Clinical Sciences Source Type: research

Restoration of the ascending reticular activating system compressed by hematoma in a stroke patient
In conclusion, restoration of nonreconstructed neural tracts of the lower ARAS with the resolution of the hematoma and perihematomal edema was demonstrated in a stroke patient, using DTT.
Source: Medicine - February 1, 2017 Category: Internal Medicine Tags: Research Article: Clinical Case Report Source Type: research

Modafinil In Debilitating fatigue After Stroke (MIDAS): study protocol for a randomised, double-blinded, placebo-controlled, crossover trial
Fatigue is a common symptom in stroke survivors for which there is currently no proven therapy. Modafinil is a wakefulness-promoting agent with established benefits in other disease models. We aim to test if m...
Source: Trials - August 17, 2016 Category: Journals (General) Authors: Thomas Lillicrap, Venkatesh Krishnamurthy, John Attia, Michael Nilsson, Christopher R. Levi, Mark W. Parsons and Andrew Bivard Source Type: research

Probable Nootropic-induced Psychiatric Adverse Effects: A Series of Four Cases
Conclusion Healthcare providers in general, and specifically those in the mental health and substance abuse fields, should keep in mind that nootropic use is an under recognized and evolving problem. Nootropic use should be considered in cases where there are sudden or unexplained exacerbations of psychiatric symptoms in patients who have been stable and medication adherent. It is also important to remember that most nootropics are not detected on standard drug toxicology screening tests. We have very little clinical information on how nootropics may interact with psychotropics (or other medications) and potentially cause ...
Source: Innovations in Clinical Neuroscience - December 1, 2015 Category: Neuroscience Authors: ICN Online Editor Tags: Case Series and Literature Review Current Issue Mental Disorders Psychiatry Psychopharmacology Substance Use Disorders Ampakines Armodafinil brain enhancer Cerebrolysin Citicoline cognitive enhancer homeopathic medicine natural r Source Type: research

Mesenchymal stem cells with modafinil (gold nanoparticles) significantly improves neurological deficits in rats after middle cerebral artery occlusion.
In this study we assessed the neuroprotective effect of modafinil-coated gold nanoparticles (AuNPs) and mesenchymal stem cell (MSC) in ischemic stroke rats. Stem cells and AuNPs offer great promise for new medical treatments. 60 male Wistar rats were randomly divided into five groups (12 in each group): (1) the group that developed middle cerebral artery occlusion (MCAO or ischemia), (2) the normal group (control), (3) the MCAO group that received MSC (C + MCAO), (4) the MCAO group that received MSC and modafinil (CM + MCAO), and (5) the MCAO group that received MSC and modafinil-coated AuNPs (CMN + MCAO). Midd...
Source: Experimental Brain Research - September 3, 2020 Category: Neuroscience Authors: Nazarian S, Abdolmaleki Z, Torfeh A, Shirazi Beheshtiha SH Tags: Exp Brain Res Source Type: research

A Review of Pharmacologic Neurostimulant Use During Rehabilitation and Recovery After Brain Injury.
CONCLUSIONS: The pharmacologic agent with the most supporting literature is amantadine used for cognitive improvement after TBI. Other neurostimulants with positive, despite more limited, evidence include methylphenidate, modafinil, levodopa, and citalopram. Caution is warranted with other neurostimulants given higher rates of adverse effects or lack of benefit observed in clinical trials. PMID: 33435717 [PubMed - as supplied by publisher]
Source: The Annals of Pharmacotherapy - January 12, 2021 Category: Drugs & Pharmacology Authors: Kakehi S, Tompkins DM Tags: Ann Pharmacother Source Type: research

Short- and Long-Term Efficacy of Modafinil at Improving Quality of Life in Stroke Survivors: A Post Hoc Sub Study of the Modafinil in Debilitating Fatigue After Stroke Trial
Thomas P. Lillicrap, Christopher R. Levi, Elizabeth Holliday, Mark William Parsons, Andrew Bivard
Source: Frontiers in Neurology - April 25, 2018 Category: Neurology Source Type: research